Davis EJ, et al. - Given the combinations of gemcitabine, 5-fluorouracil (5-FU), and platinum have demonstrated improved outcomes compared with singlet chemotherapy in pancreatic and biliary cancers, the efficacy and safety of a novel schedule of cisplatin, fixed-dose-rate gemcitabine and infusional 5-FU was evaluated in this phase II study. Findings demonstrated that biweekly cisplatin, fixed-dose-rate gemcitabine, and infusional 5-FU were well tolerated and showed a high response rate.